Fig. 1: Progression-free survival (PFS) among 18 patients with pancreatic cancer who received matched therapy.
From: Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
a PFS in 18 patients. b PFS in 5 patients who received targeted therapy as first line versus 13 patients who received it as ≥2nd line. c PFS in 11 patients with matching score ≥50% versus 7 patients with matching score <50%. CI confidence interval, PFS progression-free survival.
